genitors has been a major obstacle to the development of safe, uniformly effective therapy for children with acute lymphoblastic leukemia (ALL). Studies of isoenzymes, immunologic markers, and other expressions of cell phenotype provide valuable clues to ALL etiology, but ultimately they fail to divulge mechanisms for leukemic transformation or maintenance of the malignant state. A more fruitful approach has been to classify ALL by its cytogenetic features, both numeric and structural.' Admittedly, a proportion of the chromosomal changes reported to date have proved to be little more than genetic epiphenomena with vague links to pathogenesis and treatment outcome. This fact notwithstanding, the presence of specific cytogenetic abnormalities in leukemic cells has stimulated molecular study of genes near the chromosomal breakpoints and characterization of their protein products.' The picture emerging from these investigations is varied but has a consistent theme: genes disrupted by recurrent translocations or other chromosomal alterations tend to participate in cell regulatory pathways that control cell growth and de~elopment.~-~ Thus, cytogenetic classification of childhood ALL has the potential to suggest causative mechanisms and thereby to provide consistent guidelines for treatment. This review updates progress in the cytogenetic study of ALL and attempts to relate new findings to prognosis.
NUMERIC CLASSIFICATION
ALL can be classified into five subtypes based on the modal number of chromosomes: hyperdiploid with 47 to 50 chromosomes; hyperdiploid with more than 50 chromosomes; pseudodiploid (46 chromosomes with structural or numeric abnormalities); diploid (normal 46 chromosomes); and hypodiploid (<46 chromosomes). Recognition of ploidy as a distinctive cytogenetic feature in ALL has greatly enhanced the ability to predict clinical outcome and devise risk-specific therapy, as will be discussed in the following sections. The frequency distribution of the major ploidy groups and the 4-year event-free survival (EFS) associated with each are presented in Table I .
> 50 Chromosomes/Near-Tetraploidy
Hyperdiploidy > 50, found in 25% to 30% of cases of childhood ALL, has long been recognized as conferring the most durable responses to t~-eatment.~-'~ Patients with this feature can be rapidly identified by flow cytometric analysis of the leukemic cell DNA content, although flow cytometry does not provide information about structural chromosomal abnormalities and therefore must be used with conventional cytogenetic technique^.'^.'^ The karyotypes of patients with more than 50 chromosomes have certain features in common. One often finds extra copies of the X, 4, 6, 10, 14, 17, IS, 20, and 21 chromosomes, with duplication of Iq and isochromosome 17q observed in occasional
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Blood, Vol 81, No 9 (May 1). 1993: pp 2237-2251 recent review of 134 cases with >50 chromosomes, the frequency distribution of modal numbers peaked at 55 chromosomes, with a range of 5 I to 65." Structural chromosome abnormalities were found in 62% of these cases, including 20% with translocations. The ability to detect such alterations, including the 17q isochromosome is crucial to optimal riskgroup assignment," as patients with numeric changes only have a more favorable prognosis than do those with added structural abnormalities." Favorable presenting features commonly associated with hyperdiploidy > 50 ALL include an early pre-B immunophenotype, lower leukocyte counts, lower serum lactic dehydrogenase levels, white race, and age between 2 and I O years. The absence of T-cell features and cases in infants are notable. Investigators of the Pediatric Oncology Group recently showed that among patients with B-progenitor cell ALL, a DNA index > 1.16 (>53 chromosomes) was the strongest predictor of a favorable response to chemotherapy, regardless of the white blood cell (WBC) count.I6 They identified a subset of patients within this group who would likely fare well on antimetabolite-based treatment, excluding genotoxic agents such as cyclophosphamide, doxorubicin, and the epipodophyllot~xins.'~~~~ Near-tetraploid ALL (range of modal numbers, 82 to 94) comprises fewer than 1% of reported cases in children.2s22 Some of these cases may originate from an endoreduplication because in a few instances two copies of the abnormal chromosomes have been observed in the near tetraploid line. Alternatively, a duplication of a structural chromosome aberration may occur, providing two copies of a given abnormality. Near-tetraploid ALL is more likely to be associated with L2 morphology (30% of cases), a T-cell immunophenotype (47%) and older age (median 8.6 years), as compared with other ploidy groups in childhood ALL.23
Hyperdiploidy 47-50
This group, accounting for 10% to 15% of cases of childhood ALL,6 was initially recognized on the strength of studies indicating that 47 to 50 chromosomes confer an intermediate prognosis by comparison with all other ploidy groups.i0*" Gains of almost every chromosome have been observed in such cases, with chromosomes 8, IO, and 21 added more Treatment consisted of remission reinforcement therapy (teniposide, cytarabine, high-dose methotrexate) added to a standard four-drug induction regimen. Continuation therapy was either conventional or consisted of four pairs of drugs rotated weekly or every 6 weeks. Median follow-up was 40 months (range, 19-37 months). The 4-year EFS for all patients in this trial was 73% 2 4% SE. Adapted and reprinted with permission from Rivera et aL3* often. A case with a + I O alone was reported in a IO-year-old boy with an 800 X 109/L leukocyte count, LI cytomorphology, and a T-cell i m m~n o p h e n o t y p e .~~ A review of the literature indicates a 1.2% incidence of trisomy 8 in ALL, although the prognostic significance of this abnormality remains to be determined. 25 In a recent review of 1 1 cases with a +2 1 as the sole numeric abnormality, we found a range of presenting features that nonetheless reflected lower-risk ALL: median age 3.3 years (range 1 to 18 years), median leukocyte count 11.6 X 109/L (range 1.8 to 82 X 109/L), white race, and a B-cell precursor immunophenotype.26 Most of these patients achieved extended periods of relapse-free survival. Our analysis of 86 cases with 47 to 50 chromosomes showed +21 as the most common addition (n = 34), followed by +X (n = 18), +8 (n = 8), and $10 (n = 7).27 The chromosomal regions most often affected by structural abnormalities (76% ofthe 86 cases) were Iq (n = 13), 6q (n = 12), 12p (n = 18), and 19p (n = 9). In contrast to previous reports, the clinical outcome among patients with hyperdiploid 47-50 ALL in our Total Therapy Study XI (4-year EFS, 77% k 1 1% SE) was more in line with the hyperdiploid > 50 group than with either the pseudodiploid or hypodiploid group, suggesting that appropriately intensified therapy can offset the poor prognosis generally associated with this ploidy classification.
Pseudodiploidv
Patients whose leukemic cell chromosomes contain structural rearrangements, in the context of a diploid net chromosome number (46 chromosome^),^^^,'^ comprise the largest ploidy group in ALL (approximate incidence, 40%).28 Pseudodiploid leukemic blasts tend to be associated with bulky disease, high WBC counts, and elevated serum lactic dehydrogenase levels.lO~" The outcome of therapy in this group was extremely poor until the development of modern multiagent chemotherapy; currently, patients with pseudodiploid ALL can be expected to fare as well as most other risk groups when treated on appropriately intensified regimen^.^,^^-^* An exception are certain specific translocations, such as the t(9;22), t(4;ll) and t(8; 14) , which continue to mark highly drug-resistant disease, as will be discussed in later sections of this review.
Diploidy
The incidence of cases that lack apparent cytogenetic abnormalities in ALL varies widely, in part because of the indistinct chromosome morphology that is often encountered. It is not unusual for 10% to 15% of cases in large series to lack detectable chromosomal abnormalities by standard cytogenetic evaluation; the incidence of T-cell cases with normal karyotypes may be as high as 30%. 33 Although very rare (<I%), near-haploid cases have been extensively s t~d i e d .~~,~'~' The main clone contains at least one copy of each chromosome, with a second copy of the sex chromosomes and chromosome 2 1 found in most cases (90%). Other chromosomes found in two copies include: 18 (65%), I O (45%), and 14 (45%).35.39*41-42 In general, the morphologic features of these cases are poorly defined, and few or no structural abnormalities can be discerned. In many near-haploid cases, there is a second abnormal line with a hyperdiploid karyotype that represents a doubling of the chromosomes in the near-haploid line. This hyperdiploid line usually contains exactly two copies of all chromosomes in the near-haploid line. Several of the reported cases have included structural chromosome abnormalities in both cell lines, suggesting a common precursor cell with a near-haploid k a r y~t y p e .~~.~ Near-haploid leukemia has been associated 
STRUCTURAL CLASSIFICATION
Describing ALL by the types of structural abnormalities found in chromosomes of the leukemic clone has led to impressive advances in our understanding of leukemia pathobiology and in formulating risk-specific therapy. Molecular analysis of genes adjacent to the breakpoints of these structural anomalies and studies on the functions oftheir protein products have helped to clarify the complex interactions that promote leukemogenesis and perpetuate the leukemic cell phenotype (Table 2) . In this section, we focus on the more prominent structural abnormalities found in leukemic cells and their likely contribution to the disease process. Molecular studies have shown that the critical event in all three of these translocations is the juxtaposition of the CMYC (8q24) proto-oncogene locus with the ZGp (14q32), the IGK (2p12), or the IGX (22ql1) locus.5o These rearrangements bring the CMYC gene under the influence of transcriptionstimulating sequences in each of the active Ig loci, leading to dysregulation of CMYC, increased expression, and, presumably, neoplastic growth.51 MYC is a transcription factor that is involved in the control of cell proliferation, and its binding to DNA and activation is enhanced by the MAX and MAZ protein^.^^,^^ t(1:19)(q23:p13)/pre-B-cell ALL. The t( 1;19)(q23;p13) is the most common translocation in childhood ALL, with an overall incidence of 5% to 6%.s4-58 It is closely associated with the pre-B (cIg') immunophenotype, but may occasionally be found in early pre-B (cIg-) and T-cell cases.s6,59,60 This rearrangement occurs in either a balanced, t( 1;19)(q23;pl3) (25%), or an unbalanced, -19,+der( 19)t( 1;19)(q23;p13) (75%) form. In the unbalanced form, two normal chromosomes 1 are always present and represent a duplication of the normal homolog. Some leukemic cells contain both forms, implying that the der(1) can be lost through clonal evolution, without loss of the transformed phenotype.
B-Lineage
It has been argued that the t( 1; 19) accounts for the majority oftreatment failures in pre-B ALL.57,61 To address this point, we evaluated 112 cases of pre-B leukemia with banded karyotypes, identifying the t( 1; 19) in 25%.60 This finding was not limited to cIg+ cases; rather, the translocation was also detected in two hyperdiploid cases that had tested negative for cIg expression. The t( 1 ; 19) or der( I9)t( 1 ; 19) was the sole chromosomal abnormality in 8 of the 28 cIg+ cases. Apart from a higher incidence of translocations overall (69% v 50%), the lack of hyperdiploidy > 50 and a lower incidence of normal karyotypes (3.5% v 8% to lo%), the cytogenetic findings in our pre-B group did not differ appreciably from those reported for ALL in general. The presence of the t( 1 ; 19) correlated significantly with several recognized adverse prognostic features: higher leukocyte counts, higher serum lactate dehydrogenase levels, nonwhite race, and DNA indexes of less than 1.16. As expected, the t( 1 ; 19) was associated with an inferior outcome in patients treated on minimally or moderately intensified protocols. In a more recent study testing reinforced early treatment and rotational combination chemotherapy, the 4-year EFS for the subgroup with t( 1; 19) rearrangements was comparable with that for the entire cohort (73% k 4% SE). This improvement illustrates that effective treatment can nullify the negative impact of chromosomal rearrangements in cases of childhood pre-B ALL.32,60 Furthermore, a recent retrospective collaborative group study, for patients of all ages, reported a significantly better outcome for patients diagnosed with the balanced t( 1 ; 19) translocation when compared with the unbalanced form.62 Thus, the outcome of these subgroups should be analyzed separately.
The t( 1 ; 19) produces a critical fusion of the E2A and PBXl genes. E2A encodes the Ig enhancer binding factors E 12 and E47, and has been mapped to 1 9~1 3 :~ while PBXI, a homeobox gene of unknown function, maps to lq23.64.65 The hybrid gene possesses 5' sequences that encode a transcriptional activator domain of E2A, joined to 3' sequences that encode part of a DNA-binding homeobox domain of the PBXl gene. The structure of E2A-PBXl proteins suggests that they activate gene expression via the E2A trans-activation domain, thus contributing to malignant transformation of either pre-B cells or their progenitors. At least two forms of the chimeric protein induce malignancy when introduced into murine fibroblasts.66 Molecular detection of the t( 1 ;19) is now feasible by RNA-based polymerase chain reaction (PCR) analysis in patients with pre-B ALL.67,68 This technology has made it possible to distinguish cIg+ cases with typical E2A-PBXl transcripts from cIg-cases in which the t( 1 ; 19) does not yield similar transcripts,68 even though it appears identical to the more prevalent translocation by standard cytogenetic criteria. PCR analysis of the t( 1; 19) breakpoint may also be useful in cIg-cases with normal cytogenetic results, perhaps because of a paucity of dividing cells with the abnormality. Such distinctions may be important in devising risk-specific therapy for patients with B-lineage ALL.
/(17:19)(q22;p13)/early pre-B-cell ALL. Other nonrandom chromosomal translocations affecting band p13 of chromosome 19 may also involve the E2A gene.69, 70 We have molecularly evaluated a t( 17; 19)(q22; pl3) associated with early B-lineage leukemia and disseminated intravascular coag~lation.~' This translocation results in a chimeric transcript that contains sequences of the E2A gene fused with those of the recently discovered hepatic leukemia factor gene (HLF) on chromosome 17, which encodes a protein analogous to previously identified leucine zipper-containing transcription factors that regulate developmental stage-specific gene expre~sion.~' Disruption ofthe HLFgene by the t( 17;19) and fusion of its basic region leucine zipper domain with the transactivation domain of the E2A gene appears to be the event giving rise to leukemia in these cases. The prognostic relevance of the t( 17; 19) remains uncertain because of the limited number of cases identified to date."
The Philadelphia chromosome (Ph), or t(9;22)(q32;ql l), occurs in 2% to 5% of children with ALL.6,72-74 Clinically, Ph+ cases tend to be characterized by older age, higher leukocyte counts, larger percentages of circulating blasts, a higher frequency of FAB-L2 morphology and more prevalent pseudodiploid karyotypes than are found in Ph-cases. Most Ph+ blasts have a B-lineage immunophenotype, although isolated cases with a T-cell or mixed phenotype have been reported. Among 2,5 19 banded cases of childhood ALL, 58 (2.3%) were Ph+.73 Children with this karyotypic feature had a median leukocyte count of 33 X 109/L and a median age of 9.6 years; most had FAB-L2 cytomorphology. The immunologic marker distribution was similar to that in the Ph-cases: early pre-B ALL, 75%; pre-B-cell, 16%; and T-cell, 9%. Cytogenetic evaluation identified the classic t(9;22)(q34;q 11) in 85% of the 58 cases; the remainder had a complex translocation involving an additional chromosome or a chromosome 22 translocation with no microscopically visible involvement of 9q34 in the formation of the t(9;22). The Philadelphia chromosome was found as a single abnormality in approximately 50% of the cases. t(9;22)(q32;ql l)/B-cell precursor ALL.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From Pseudodiploidy was the most frequent modal number (n = 34), followed in decreasing order by hypodiploidy (n = 1 9 , hyperdiploidy 47-5 1 (n = 5), and hyperdiploidy > 5 1 (n = 4). A significantly lower proportion of Ph+ patients entered complete remission on a protocol of intensive chemotherapy compared to the result for patients without this feature (78% v 96%). Moreover, by 4 years of follow-up, approximately two thirds of Ph+ responders had relapsed.73 The consistent lack of success in treating this form of ALL has prompted most investigators to consider bone marrow transplantation (BMT) in first remission as a therapeutic option.
Russo et a175 found partial or complete monosomy 7 in approximately 25% of 57 children with Ph+ ALL. This observation is notable because the loss of one copy of chromosome 7 generally characterizes myeloproliferative disorders that progress to acute myeloid leukemia.76 This subgroup of children with Ph+/-7 ALL comprised mainly older males with early B-lineage ALL, whose induction failure rate (3 1%) was much higher than that among Ph-cases. These findings suggest that leukemic transformation in such patients is a multistep process involving the interaction of a dominant oncogene (Ph; BCR-ABL) with a tumor suppressor gene (-7).
Cytogenetically, the Ph chromosome in ALL is identical to that seen in chronic myeloid leukemia (CML), where the marker is retained throughout the course of the disease. By contrast, when children with Ph+ ALL achieve complete remission, the Philadelphia chromosome is no longer apparent on cytogenetic analysis. At the molecular level, the two translocations are d i f f e r e~~t .~~.~' In cases of CML with the t(9;22) the ABL proto-oncogene on chromosome 9 at q32 joins to a 5.8-kb region on chromosome 22 (qll) known as the breakpoint cluster region (bcr), which lies within a larger gene, BCR.77-79 This results in a unique 8.5-kb mRNA that encodes a 2 10-Kd protein, p210.'' By contrast, in most cases of ALL, the ABL proto-oncogene fuses to a region 5' of the bcr within the BCR gene, resulting in a smaller mRNA transcript and a 190-Kd protein, p 1 90.81*s2 Both proteins are tyrosine phosphokinases and are thought to play a critical role in the control of cell pr~liferation.'~ Cloning the t(9;22) translocation has provided the DNA probes for the molecular evaluation of its breakpoints. By using polymerase chain reaction (PCR) to amplify the translocation junction in cases of both CML and ALL, the clinical status of these patients can be m~nitored.'~ At this time, the clinical significance of the continuing presence of the Ph chromosome (minimal residual disease) is not understood.
t(4;l l)(q21;q23)/B-ceN precursor ALL. The t(4; 11) (92 I ;q23) has been associated with lineage heterogeneity, the absence of hyperdiploidy, hyperleukocytosis, anemia, CNS involvement, young age at presentation, and a poor prognosi~.~~-'' The frequency of this translocation in childhood leukemia has been uncertain because the few published series have been small. Most reported cases have occurred in children younger than l year, commonly newboms.86.88 By many criteria-morphologic, cytochemical, ultramicroscopic, immunologic and molecular-blast cells with the t(4;ll) have been shown to have mixed lymphoid and myeloid features. Most cases of ALL with this translocation have a B-cell precursor phenotype (pre-B or early pre-B), with the blast cells containing rearranged Ig heavy-chain genes and expressing HLA-DR but lacking sheep erythrocyte receptors or surface Ig. Moreover, after treatment with the differentiation-inducing agent 12-0-tetradecanoyl-phorbol-13-acetate (TPA), blasts containing the t(4; 1 1) acquire ultrastructural, cytochemical, and immunologic properties of monocyte^.'^ The finding of monocytic features in cells with characteristics of B-cell precursors has suggested that leukemias with the t(4; I 1) arise in a stem cell with the potential to differentiate in both the lymphoid and myeloid pathways.
In a collaborative study, the t(4;l l)(q2 l;q23) was identified in 40 (2%) of 1986 children with newly diagnosed ALL?'
This translocation was associated with female sex (60%), age less than I year (60%), hyperleukocytosis (median leukocyte count, 156.5 X 109/L), an early pre-B-cell immunophenotype (79%), and myeloid-related antigen (CD 15) expression (63%). Leukemic cell L2 morphology was found in 13% of the cases. Of the 32 cases in which myeloid-associated antigen expression was analyzed, 20 had significant CD 15 positivity. Seventy-three percent of the 40 cases had the t(4;ll) as the sole chromosome abnormality. The modal chromosome numbers of the leukemic cell lines were 46 (n = 36), 47 (n = 2), 48 (n = I), and 82 (n = 1). Notably, none of the 40 cases had hyperdiploidy > 50 but less than 80, a favorable cytogenetic feature. Analysis of clinical presenting features by age < 1 year (n = 24), 1 to 9 years (n = 8), and 210 years (n = 8)
showed that infants were significantly more likely to have initial CNS leukemia and less likely to have pre-B-cell ALL. Despite contemporary intensive therapy, complete remission was maintained in only 7 of 24 infants and in only 2 of 8 adolescents, in contrast to 7 of 8 children in the intermediate age group (8 of the 16 cases remaining in remission have been followed for < 1 year)?' These results suggest that BMT or novel methods of chemotherapy should be considered for infants or adolescents with the t(4;ll). The q23 region of chromosome I 1 is a relatively frequent site of structural rearrangements in ALL.9',92 As observed for the t(4;l I), patients with 1 lq23 abnormalities are usually younger, and have higher leukocyte counts than do subgroups lacking this alteration. Although isolated cases have a T-cell immunophenotype, there is a strong concordance between 1 lq23 abnormalities and the early B-lymphoid, CDIO-immunophenotype. Including cases with the t(4; I l), 1 lq23 abnormalities have been mainly associated with early pre-B-cell ALL, appearing in the blast cells of 4.5% to 5.7% of patient^.^',^' A disturbing trend has been the development of secondary leukemia with I lq23 alterations in patients, mainly adults, who received genotoxic agents for neuroblastoma, Hodgkin's disease, osteogenic sarcoma, or breast c a n~e r .~~-'~ In children, use of one or both of the epipodophyllotoxins (VM-26 and VP-16) has been implicated in the induction of secondary myeloid leukemias after treatment for ALL; in most instances, the secondary leukemia is of the monocytic or myelomonocytic subtype with characteristic 1 lq23 abn~rmaIities.~~-~' Most cases of translocations involving the 1 lq23 region result from exchanges with chromosome 4; however, chromosomes 1, 10, and 19 can also contribute to this process,
lq23 abnormalities/early pre-B-cell ALL.
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as exemplified by the t( 1;1 l)(p32;q23), t( 1O;l l)(p14-p15;q22-q23) and t(l1;19)(q23;~13).~~ Other random and nonrandom translocations involving the 1 lq23 band [eg, the t(9;l l)(p22;q23), t(6;l l)(q27;q23)] are found more often in acute myelomonocytic and monocytic l eukemi as, ' @' although the t(9;l l)(p22;q23) can be found in rare cases O~A L L .~' , '~' A recurrent constitutional t( 1 I ;22)(q23;ql I), not associated with disease, has also been localized to this region of chromosome 1 I . lo' The diverse chromosomal abnormalities involving band 1 lq23 are indistinguishable by light microscopy; translocations affecting this chromosomal region probably map to the same locus and may play an important role in malignant transformation. IO3 Several genes that encode proteins active in cell signaling have been localized to this region: eg, THYI, NCAM, genes encoding the 7 , 6, and t subunits of the T3 moiety of the Tcell receptor (TCR) complex, and the ETSl and CBL2 protooncogene^.^^ Preliminary mapping of the 1 lq23 region indicates orientation of these genes: as centromere, NCAM, CD3, THYI, CBL2, and ETS1.'04-'06 The ataxia telangiectasia locus (AT) has also been mapped to the 1 lq23 region, presumably centromeric to the THY1 locus.1o7 Results of recent molecular investigations have identified an additional gene that may be associated with this breakpoint. Designated MLL (myeloid, lymphoid leukemia or mixed lineage leukemia), it spans the llq23 region in the t(4;11), t(6;11), t(9;ll) and t( 1 I ; 19) translocations and is between the CD3 gene cluster and PBGD, which is distally located to CD3.'03,1083'09 The MML gene appears identical to the ALL1 locus reported by Cimino et aliLO,"' and may be responsible for the unique presenting features of leukemias characterized by alterations in the I lq23 region. Although most 1 lq23 translocation breakpoints cluster between genes CD3G and PBGD, a few reports indicate a diverse location, implicating additional unknown proto-oncogenes in this region. '04~112~"3 ALL in infants shows preferential involvement of the 1 lq23 region, not limited to the t(4;l 1)."""6 In a recent study of the Pediatric Oncology Group, 35 of 52 infants less than 1 year old had an abnormal karyotype, which included rearrangement of the 1 lq23 region in 21 cases.Ii7 Results of this and other studies substantiate the impression that 1 lq23 alterations may preferentially affect stem cells capable of development in either the myeloid or lymphoid pathway. Further molecular investigation of the diverse breakpoints at 1 lq23 is needed to establish the relationship between cytogenetic alterations in this region and the leukemic transformation of blast cells.
T-cell Leukemia-Lymphoma
T-cell childhood leukemia, accounting for about 15% of cases of ALL, has a relatively poor prognosis that can be attributed in part to hyperleukocytosis, frequent involvement of the CNS, mediastinal enlargement, and the lack of hyperdiploid > 50 chromosomes. Paradoxically, a lower percentage of patients have cytogenetically detectable abnormal clones compared with findings in other immunophenotypes of ALL.24,32*34*"8-121 Approximately 30% to 40% of the abnormal karyotypes in T-cell leukemia have nonrandom breakpoints within the 14ql1, 7q34-q36, or 7p15 region, which contain the TCRa/6, TCRP, and TCRy genes, respectively."' The four identified loci undergoing structural rearrangement during T-cell differentiation are analogous to the Ig genes in B-cell development. Results of earlier studies with in situ hybridization and somatic cell genetic techniques suggested that inversions and translocations disrupt the a-TCR genes in some T-cell malignan~ies."~~"~ Recent molecular studies have confirmed these observations in numerous chromosomal rearrangements, mainly involving the 14qll and 7q34-q36 regions ( Table 2 ). The prominent recurring chromosomal abnormalities in T-cell ALL are discussed in the following sections.
The most frequent nonrandom abnormality in childhood T-cell ALL is the t( 11;14)(p13;ql I), detected in 7% of cases.34~54~"6~127 At the molecular level, the breakpoint is within the 0116 locus of the TCR gene on chromosome 14.124~'*8~'29 Th e breakpoints in I 1 p 13 are clustered within a region of less than 25 kb, termed T-ALLkr, suggesting that a specific gene is altered by the t r a n s l o~a t i o n . '~~-'~~ The t(ll;l4)(pl5;qll), found in 1% of T-cell neoplasias, 127.134 also disrupts the a/& locus of the TCR gene on chromosome 14.135 On chromosome I 1 the break occurs in a gene named TTGl (T-cell translocation gene 1) or rhomboth 1 (RBTNI), which encodes a nuclear protein whose structure has been highly conserved among diverse species, suggesting an important functional role in ontogeny (eg, brain development). 136,137 Interestingly, another rhombotin-related gene (RBTN2) was found near the previously described TALLkr region or chromosome I lpl3, TTG2,137 a newly recognized gene encoding a cysteine-rich protein with a LIM motif, is overexpressed in T-cell ALL defined by the t( 11;14)(p13;ql 1).138 Hence, members of the rhombotin gene family may be a class of transcription factors with particular relevance for T-cell neoplasia.
Reported in 5% to 10% of patients with T-cell ALL and lymphomas,'39 the t( 10;14)(q24;ql I ) occurs in the TCRG locus on chromosome 14 and in a breakpoint cluster region on chromosome 10.'40-142 The tight clustering of t( 1034) breakpoints on chromosome I O at q24 suggests that the translocation may result in dysregulation of a newly identified homeobox gene, termed HOXl I , via illegitimate physiologic recombination with TCR6. i43- 145 The HOXl1 gene shares homology with other homeobox-containing genes that normally code for sequence-specific DNA binding proteins and when abnormally expressed may contribute to T-cell leukemogenesis. Because of the tight clustering of chromosomal breakpoints, the t( 10; 14) can be detected by PCR analysis. 146 The t(8;14)(q24;qll) is commonly observed in T-cell leukemias (2%) but is not restricted to this lineage.34*'47s148 At the molecular level, the TCRa gene is rearranged with the CMYC oncogene, resulting in its transcriptional dysregulat i~n . '~~-'~'
In this translocation, the breakpoint occurs between the variable and constant regions of the TCR, resulting in translocation of the constant region distal to the CMYC gene, which corresponds to the mechanisms of CMYC activation in the variant B-cell trans location^.'^^-'^^ A t( 1;14)(p32-p34;ql I ) has been observed in 3% of T-cell ALL patients. 155 
Molecularly, TALI (SCLI/TCLS) is juxtaposed with the TCRal6 chain locus on chromosome 14ql I(TCRa/G).
14.156-159
The amino acid translation of TALI or SCL includes sequences containing a helix-loophelix motif, a DNA-binding domain present in a family of proteins involved in the control of cell growth and differentiati~n.'~~ Subsequently, a site-specific chromosomal deletion was identified that involved SCL and a locus called SIL (for SCL-interrupting Iocus).'~'-'~~ The deletion, which occurs in 15% to 26% of patients with T-cell ALL, cannot be observed by karyotypic analysis but is easily detected by Southern blotting or PCR analysis. Some investigators have speculated that the SZL/SCL deletion contributes to malignant transformation in a manner similar to that of the t( 1;14), which also disrupts the 5' regulatory region of SCL. 160,165,166 Hence, alteration of TALl, either by translocation or other rearrangement, represents the most common genetic lesion associated with T-lineage leukemia. Most importantly, the TALI interstitial deletion is the first known instance whereby two genes (neither of which is an antigen receptor gene) are joined through the action of the V(D)J recombinase system.I6'
The 7qter region containing the TCRP gene is affected by chromosomal aberrations less often than the a/6 region of chromosome 14.167-170
Molecular evaluation of T-cell lines with a t(7;9)(q34;q34) showed that the breakpoint on chromosome 7 was within the TCRP gene but no alteration of the ABL oncogene was found on chromosome 9.'71,172 Another study of a similar case demonstrated consistent breakage between consensus recombinase heptamers of chromosome 9.'73 It has also been shown that the affected region on chromosome 9 contains a gene (TANl) that is highly homologous to the Drosophila gene Notch; TANl is broken by the t(7;9)(q34;q34), producing a truncated version of TANl mRNA.174 Recently, a helixloophelix TAL2 gene was identified on chromosome 9 at q32 is transcriptionally activated by a t(7;9)(q34;q32).'75 A t(7; 19)(q34;p 13) in a T-cell line established from a case ofT-cell ALL affects the TCRP gene and truncates the LYLI gene,'76 which is quite homologous to the TALl gene,166 and whose protein product contains a potential helix-loop-helix DNA-binding motif and may therefore contribute to leukemogenesis. 177 Similarly, in two cases of T-cell ALL, a t( 1;7)(p34;q34) impinged on the TCRP locus and interrupted the LCK locus on chromosome 1p34.178,179 The LCK gene encodes a protein kinase, p56Ick, which is normally restricted to lymphoid cells and is considered to play a crucial role in the transduction of mitogenic signals.'*' Thus, the alteration in the promoter region of the LCK locus may play a role in human cancer. We evaluated molecularly a cytogenetically different t( 1;7)(p32;q35) that placed the TALI locus near the TCRP enhancer, which may overexpress the TAL gene product and thus contribute to leukemogenesis.18' A t(7; I l)(q35;p13) and a t(7;10)(q35;q24), variants of the more frequently observed t(l1;14)(p13;qll) and t(10;14)(q24;ql I), respectively, also activate DNA-binding transcription factors (RBTN2 and 7935 (TCR6)).
HOX I 1 ).182,183
NonspeciJc Lineage 6q abnormality. Deletion of the long arm of chromosome 6 is a relatively common finding in ALL, reported in 4% to 13% of cases, most of which have the breakpoints localized to 6q15 and 6q2 l.3+8,'3 In a review of 412 consecutive cases of ALL with fully banded karyotypes, we identified 45 ( I 1%) with a 6q abnormality.lS4 Eighty-five percent of the alterations were deletions, with other types of structural rearrangements accounting for the remainder. The presenting features and EFS of children with a 6q abnormality were not demonstrably different from those of patients lacking this feature. There was no indication of immunophenotype specificity for these changes, suggesting that the gene or genes affected by 6q abnormalities are broadly active in the multistep process of lymphoid leukemogenesis, or perhaps arise as molecular epiphenomena of more specific lesions. No conclusive molecular evidence for loss of heterozygosity has been reported for 6q deletions. I " J 86 Abnormalities of the short arm of chromosome 9 (9p) have been observed in 7% to 12% of cases of childhood ALL.I8'-I9' Earlier reports indicated that 9p abnormalities were usually associated with a "lymphomatous" type of ALL, often characterized by a T-cell immunophenotype with prominent lymphadenopathy, mediastinal enlargement, and s p l e n~m e g a l y . '~~~~~~ Subsequent reports describe 9p abnormalities in a significant number of B-lineage case^.'^^^'^^ In our own large series of consecutively banded cases of ALL, there was a 10% incidence of 9p abnormalities (26 deletions, 9 unbalanced and 5 balanced translo~ations).l~~ Compared with patients lacking this change, the affected children were older and had higher leukocyte counts, a greater frequency of splenomegaly and the T-cell immunophenotype (25%), and an increased rate of extramedullary relapse. We initially concluded that despite their association with highrisk clinical features, 9p abnormalities did not predict any major adverse events in the clinical course, except for an apparently increased hazard of involvement of the CNS (eight of I7 failures). More recently, however, in a clinical trial of intensified chemotherapy, patients with 9p abnormalities, whether translocations or deletions, had an inferior outcome (4-year EFS of 50% v 73% for the study The "critical" region involved in 9p abnormalities is p2 1-p22,'92,193 which encompasses the interferon-a gene cluster (IFNA) and the interferon-6-1 gene (IFNBI), both of which are included within the segments known to be deleted in some ALL cases with or without cytogenetic abnormalities of 9p.'92-194 Conceivably, these deletions lead to loss of a tumor suppressor gene located in the 9p region. A deficiency of the enzyme methylthioadenosine phosphorylase (MTAP), mapped to 9p, was found in many cases of IFN gene deletion, suggesting a link between these genes.I9' Abnormalities of the p arm of chromosome 12 appear in approximately 10% of cases of ALL.119.'96 A breakpoint at band p12 is reported most often, although breaks at both pi 1 and p13 are seen as well. Most cases with a 12p abnormality have a B-lineage immunophenotype, although some T-cell cases have also been reported. Among 632 banded cases of ALL,I9' the 12p abnormalities consisted of 20 deletions, 22 balanced translocations, 16 unbalanced translocations, 14 dicentric chromosomes, and 4 inversions for an overall incidence of 12%. Abnormalities seen in more than one case were the t(1;12)(q22;p12), n = 9p abnormality.
12p abnormality.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From 2; t(6;12)(q21;p12), n = 2; t(12;13)(p13;q14), n = 2; dic(9;12)(pll;p12), n = 5; dic(7;12)(pll;p12), n = 5; dic( 12;17)(pl I;pl I), n = 2; del(l2)(p1 I), n = 7; del(l2)(p12), n = 13; and inv( 12)(pl3q22), n = 3. A 12p change was the sole chromosomal abnormality in only 30% of the 74 cases; the modal numbers were 45 (17.6%), 46 (58%), 47 to 50 (24%), and >50 (5.4%). The 4-year EFS in patients with a 12p abnormality is excellent (83% * 12% SE).32 Likewise, one of the most frequent recurrent 12p abnormalities, dicentric (9; 12)(plI ; p 12), is associated with B-progenitor phenotype and a good prognosis. 19' The remarkable heterogeneity of the observed changes suggests that a gene or genes located on 12p may be relevant to leukemogenesis and rearranged with loci from several other chromosomes. The neoplastic process may also be triggered by loss of heterozygosity via deletions or dicentric formations.
We recently identified seven new recumng translocations among 483 cases of ALL with adequate chromosome banding studies. '99 Four were apparently balanced [t(1;3)(p34;p21), t(7;9)(p15;p23-p24), t(12;13)-(p13;q14), t( 17;19)(q22;p13)], while three were unbalanced with the formation of a dicentric chromosome [dic(7;9)-(p13;pl I), dic(7;12)(pl l;p12), and dic( 12;17)(plI;pl I-p12)].
The small size of these subgroups prevented definitive correlations with clinical presenting features or immunophenotype, except for the t( 17; 19), as indicated previou~ly.~' Nonetheless, rare translocations in ALL may prove biologically important. For example, a distinct subtype of B-lineage ALL is associated with peripheral eosinophilia and a t(5;14)(q31;q32).200 It has been shown that the IL3 and fGp genes are joined by this translocation,"' resulting in activation of the former.202
Rare translocations.
METHODOLOGIC ADVANCES
The use of chromosome-specific DNA probes in conjunction with fluorescence in situ hybridization (FISH) permits the detection of both numeric and structural aberrations in metaphase spreads as well as interphase nuclei. 203 In this approach, the "target" DNA in the nuclei or chromosomes is denatured and hybridized to chemically modified (eg, biotinylated), single-stranded nucleic acid "probe" sequences that are homologous to the genomic DNA sequences selected for staining.'04 The reaction conditions are adjusted so that hybridization occurs only between the probe and target DNA sequences with the greatest homology. The bound probe is made fluorescent by treating with a reagent (eg, fluoresceinlabeled avidin). All target DNA can be visualized by counterstaining with a DNA-specific fluorescent dye (eg, propidium iodide) that emits in a different spectral range. [205] [206] [207] The power of the FISH method stems from the increasing availability of chromosome-or locus-specific nucleic acid probes, of three general classes: (1) probes for sequences that are present in many copies on one c h r o m o s~m e~~~'~'~: (2) composite probes composed of many individual elements that are homologous to target sequences distributed moreor-less continuously along an entire c h r o m~s o m e~'~~~'~; and (3) probes homologous to a specific chromosome subregion or locus (eg, those associated with a genetic d i~e a s e ) .~'~-~'~ FISH provides only limited information about the karyotype of leukemic cells, but when used in conjunction with conventional cytogenetic techniques, it has specific advantages that make it useful in both the clinical management of patients and the study of leukemia pathobiology.220 For example, it can be applied to the study of nondividing or slowly dividing cells, making it useful in assessing terminally differentiated blood cells or cells that are difficult to grow in culture.2'1.z21 In one of the many applications of FISH, it may be possible to screen large numbers of cells for residual disease in patients in "complete remission" from acute leukemia with known numeric chromosomal a b n o r m a l i t i e~,~'~.~'~ or in hypoplastic or mismatched sex marrows of patients after a bone marrow tran~plant."~ 11. Secker-Walker LM, Chessells JM, Stewart EL, Swansburry GJ, Richards S, Lawler SD: Chromosomes and other prognostic factors in acute lymphoblastic leukaemia: A long-term follow-up. Br J Haematol 72:336, 1989 For 
